Last reviewed · How we verify
Risedronate
At a glance
| Generic name | Risedronate |
|---|---|
| Also known as | Sedron 35mg tablet, Actonel, ACTONEL®, ATELVIA®, actonel |
| Sponsor | Toronto Rehabilitation Institute |
| Target | Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
Approved indications
- Glucocorticoid Induced Osteoporosis
- Osteitis deformans
- Osteoporosis
- Postmenopausal osteoporosis
- Prevention of Glucocorticoid-Induced Osteoporosis
Common side effects
- Diarrhea
- Abdominal pain
- Constipation
- Vomiting
- Dyspepsia
- Nausea
- Abdominal pain upper
- Influenza
- Bronchitis
- Upper respiratory tract infection
- Arthralgia
- Back pain
Drug interactions
- Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations
- Histamine 2 (H2) blockers and Proton Pump Inhibitors (PPIs)
- Estrogens and estrogen agonist/antagonists
- Aspirin/Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Key clinical trials
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (PHASE3)
- Rise & Renew: Supporting Well-Being in Black Women After the Loss of a Loved One (NA)
- Effects of Bisphosphonates on OI-Related Hearing Loss (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women (PHASE4)
- Denosumab Safety Assessment in Multiple Observational Databases
- A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risedronate CI brief — competitive landscape report
- Risedronate updates RSS · CI watch RSS
- Toronto Rehabilitation Institute portfolio CI